Gamma Knife Market Market Size, Share, Growth, and Industry Analysis, By Types (Head Gamma Knife System,,Body Gamma Knife System), By Applications (Brain Metastasis,,Cancer,,Arteriovenous Malformation (AVM),,Trigeminal Neuralgia,,Others) , and Regional Insights and Forecast to 2035

Gamma Knife Market Market Overview

The global Gamma Knife market size was valued at USD 217.84 million in 2026 and is projected to grow from USD 639.13 million in 2026 to USD 639.13 billion by 2035, exhibiting a CAGR of 3.2% during the forecast period.

The Gamma Knife Market Market represents a specialized segment within the global stereotactic radiosurgery ecosystem, focused on non-invasive treatment of brain tumors, vascular malformations, and neurological disorders. The Gamma Knife Market Market Report highlights the increasing adoption of precision radiation technologies across neurosurgical centers and oncology institutes worldwide. More than 1 million patients have undergone Gamma Knife procedures globally, with over 350 dedicated Gamma Knife centers operating in hospitals and specialty neurology clinics. Gamma Knife systems typically deliver radiation accuracy within 0.15 mm, making them highly effective for treating over 30 brain conditions including trigeminal neuralgia, acoustic neuromas, and metastatic brain tumors. The Gamma Knife Market Market Analysis shows that over 65% of stereotactic radiosurgery procedures targeting intracranial lesions are performed using Gamma Knife technology. Increasing neurological disorder prevalence, which affects nearly 15% of the global population, continues to strengthen the Gamma Knife Market Industry Analysis and expand Gamma Knife Market Market Opportunities for hospitals investing in advanced radiation therapy platforms.

The United States represents the largest installed base of Gamma Knife systems worldwide, supported by advanced neurosurgical centers and growing demand for non-invasive treatment of brain tumors, arteriovenous malformations, trigeminal neuralgia, and functional neurological disorders. Leading academic hospitals continue to expand stereotactic radiosurgery programs, improving patient access to outpatient procedures. The latest Gamma Knife platforms feature 192 cobalt-60 radiation sources with submillimeter targeting accuracy, enabling highly precise treatment while preserving healthy brain tissue. Increasing adoption of image-guided radiosurgery, rising incidence of brain metastases, and continued investments in neuroscience infrastructure are strengthening the U.S. Gamma Knife market across hospitals and specialized cancer centers.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Over 62% procedural preference for non-invasive stereotactic radiosurgery, 58% reduction in hospital stays compared with open neurosurgery, 47% increase in neurological tumor detection, 53% clinical adoption of targeted radiation therapies, and 49% hospital technology upgrades toward precision radiosurgery platforms.
• Major Market Restraint: Approximately 41% hospitals report high installation cost barriers, 38% healthcare systems face budget limitations for radiosurgery systems, 36% clinical centers depend on government funding, 33% operational expenses affect adoption, and 29% smaller hospitals lack specialized neurosurgical infrastructure.
• Emerging Trends: Around 57% integration of AI-assisted treatment planning, 52% rise in robotic patient positioning systems, 46% hospitals adopting frameless radiosurgery solutions, 44% increase in outpatient radiosurgery procedures, and 39% growth in advanced imaging-guided stereotactic treatment platforms.
• Regional Leadership: North America accounts for nearly 48% advanced radiosurgery installations, Europe represents 27% specialized neurosurgery centers, Asia Pacific contributes about 18% new technology adoption, while Middle East and Latin America collectively represent nearly 7% emerging clinical installations.
• Competitive Landscape: Approximately 45% market concentration among leading radiation technology manufacturers, 32% investment in R&D for radiosurgery precision, 28% expansion of hospital partnerships, 25% product innovation focused on treatment planning software, and 22% strategic collaborations in neurosurgical equipment development.
• Market Segmentation: Around 64% demand for head-focused Gamma Knife systems, 36% adoption of body-targeted radiosurgery variants, 58% utilization in brain tumor treatment, 23% application in vascular malformations, and 19% treatment use for functional neurological disorders.
• Recent Development: Nearly 51% hospitals upgrading to next-generation radiosurgery platforms, 44% expansion of neurological treatment centers, 37% improvement in radiation accuracy technologies, 33% increase in AI-enabled treatment planning adoption, and 29% growth in precision imaging integration.

Gamma Knife Market Market Latest Trends

The Gamma Knife Market Market Trends are strongly influenced by technological advancement in stereotactic radiosurgery and the increasing burden of neurological diseases worldwide. More than 60% of neurosurgery centers are now integrating advanced imaging modalities such as MRI-guided treatment planning and 3D dose mapping to improve targeting precision. The Gamma Knife Market Market Insights also indicate that over 55% of hospitals are transitioning toward frameless radiosurgery technologies that reduce patient discomfort while maintaining sub-millimeter accuracy. Increasing prevalence of brain metastases remains a significant factor shaping the Gamma Knife Market Market Growth, as nearly 20–40% of cancer patients develop secondary brain tumors requiring targeted radiation therapy. Another trend shaping the Gamma Knife Market Industry Analysis is the growing adoption of outpatient radiosurgery procedures, with approximately 48% of treatments now conducted without overnight hospitalization. 

Gamma Knife Market Market Dynamics

DRIVER

"Rising prevalence of neurological disorders and brain tumors"

The primary growth driver in the Gamma Knife Market Market Analysis is the increasing incidence of neurological disorders and brain tumors requiring non-invasive treatment. Nearly 25 million people worldwide are affected by brain and central nervous system disorders that require specialized neurosurgical intervention. Approximately 20–40% of cancer patients develop brain metastases during disease progression, creating strong demand for targeted radiosurgery technologies such as Gamma Knife systems. Gamma Knife treatment provides radiation accuracy within 0.15 mm and allows treatment of more than 30 neurological conditions without open surgery. Over 65% of neurosurgical centers prefer stereotactic radiosurgery due to shorter recovery periods and reduced hospitalization rates. Furthermore, patient preference for minimally invasive procedures has increased by nearly 52% across oncology treatment centers. Increasing survival rates for cancer patients have also expanded the population requiring brain metastasis management, with more than 200,000 new cases identified annually in developed healthcare systems. These clinical and demographic trends continue to strengthen Gamma Knife Market Market Growth and encourage hospitals to invest in advanced radiosurgery infrastructure.

RESTRAINTS

"High equipment installation and operational costs"

One of the most significant restraints in the Gamma Knife Market Market Research Report is the high capital cost associated with acquiring and maintaining radiosurgery systems. Installation of a Gamma Knife unit requires specialized radiation shielding infrastructure, advanced imaging systems, and dedicated neurosurgical teams. Nearly 41% of hospitals report financial constraints when evaluating investment in stereotactic radiosurgery equipment. Maintenance and operational expenses also represent a considerable burden, as approximately 36% of healthcare facilities indicate difficulty sustaining long-term operational budgets for advanced radiation therapy equipment. In addition, specialized training requirements for neurosurgeons, medical physicists, and radiation oncologists limit adoption in smaller hospitals and developing healthcare systems. Nearly 33% of healthcare institutions lack the clinical expertise required for Gamma Knife treatment planning and patient management. Budget limitations within public healthcare systems further reduce equipment procurement, particularly in emerging markets where advanced radiosurgery infrastructure remains limited. These financial and operational barriers slow the pace of technology adoption despite strong clinical demand for precision radiosurgery solutions.

OPPORTUNITY

"Expansion of neurosurgical treatment centers in emerging economies"

The Gamma Knife Market Market Opportunities are expanding rapidly due to the growing development of advanced neurosurgical facilities in emerging healthcare markets. Countries across Asia Pacific, the Middle East, and Latin America are investing heavily in specialized oncology and neurological treatment infrastructure. Approximately 45% of newly established neurosurgery centers globally are located in emerging economies where neurological disease incidence is rising rapidly. Healthcare modernization programs and government investments in cancer treatment infrastructure are enabling hospitals to integrate advanced radiosurgery technologies. In several developing regions, neurological disorders affect nearly 12–15% of the population, creating substantial demand for minimally invasive treatment options. Additionally, global cancer incidence continues to rise, with more than 19 million new cancer cases diagnosed annually, many of which lead to brain metastases requiring stereotactic radiosurgery treatment. Hospitals are increasingly prioritizing non-invasive treatment technologies to improve patient outcomes and reduce hospitalization burdens. As awareness of precision radiation therapy increases, the Gamma Knife Market Industry Report suggests that adoption across emerging healthcare systems will continue expanding clinical treatment capacity worldwide.

CHALLENGE

"Limited availability of specialized neurosurgical expertise"

A major challenge affecting the Gamma Knife Market Market Outlook is the shortage of trained neurosurgeons and radiation specialists capable of operating advanced radiosurgery systems. Gamma Knife procedures require multidisciplinary coordination between neurosurgeons, radiation oncologists, and medical physicists to design highly accurate treatment plans. However, nearly 38% of healthcare institutions report difficulty recruiting qualified radiosurgery professionals. Training programs for stereotactic radiosurgery remain limited, with fewer than 30% of medical institutions offering specialized education in advanced radiosurgery techniques. In addition, the complexity of treatment planning software and imaging systems increases the learning curve for clinical staff. Hospitals in developing regions often lack access to experienced neurosurgeons, which reduces their ability to implement Gamma Knife technology even when equipment is available. The growing demand for neurological treatment further intensifies workforce shortages, particularly in regions where patient volumes are increasing rapidly. Addressing this expertise gap will be essential for expanding the Gamma Knife Market Market Growth and ensuring consistent treatment quality across healthcare systems.

Gamma Knife Market Market Segmentation

The Gamma Knife Market Market Segmentation is categorized based on system type and clinical application across neurosurgical treatment environments. The Gamma Knife Market Market Insights highlight growing demand for advanced stereotactic radiosurgery technologies capable of delivering highly targeted radiation therapy for neurological conditions. Segmentation by type focuses primarily on head-focused Gamma Knife systems and extended radiosurgery solutions designed for broader treatment capabilities. Increasing demand for non-invasive brain tumor treatment, trigeminal neuralgia therapy, and vascular malformation management continues to drive segmentation expansion within hospitals and specialized neurology centers worldwide.

Download FREE Sample to learn more about this report.

BY TYPE

Type name: Head Gamma Knife System: Head Gamma Knife systems represent the most widely utilized technology in the Gamma Knife Market Market Analysis due to their exceptional precision in treating intracranial disorders. These systems are designed specifically for brain tumor treatment and stereotactic radiosurgery targeting delicate neurological structures. Nearly 70% of stereotactic radiosurgery procedures globally utilize head-focused Gamma Knife platforms because of their high radiation accuracy and ability to treat lesions smaller than 3 millimeters. Clinical studies indicate that approximately 85% of treated brain metastases respond effectively to Gamma Knife radiosurgery with minimal impact on surrounding healthy tissue. Head.

Type name: Body Gamma Knife System: Body Gamma Knife systems represent an emerging technological development within the Gamma Knife Market Industry Analysis as hospitals expand radiosurgery capabilities beyond intracranial treatments. These systems integrate stereotactic radiation technology with advanced imaging guidance to treat tumors located in other critical areas of the body. Approximately 36% of radiosurgery technology adoption now includes body-focused stereotactic treatment platforms capable of targeting spinal tumors, lung lesions, and liver metastases. Medical centers using body Gamma Knife technology report nearly 48% improvement in treatment precision compared with conventional radiation therapy methods. 

BY APPLICATION

Application name: Brain Metastasis: Brain metastasis represents one of the most significant clinical applications in the Gamma Knife Market Market Analysis because a large proportion of cancer patients develop secondary tumors in the brain. Medical statistics indicate that nearly 20–40% of cancer patients experience brain metastases during disease progression, making stereotactic radiosurgery an essential treatment approach. Gamma Knife technology is capable of delivering highly concentrated radiation doses with targeting precision close to 0.15 mm, enabling treatment of multiple metastatic lesions in a single procedure. Around 65% of radiosurgery procedures for intracranial metastases are performed using Gamma Knife systems due to their ability to protect surrounding brain tissue. Clinical outcomes indicate that approximately 80% of treated metastatic tumors show controlled growth following radiosurgery procedures. Additionally, over 70% of patients undergoing Gamma Knife treatment for brain metastases can avoid open brain surgery, significantly reducing hospitalization duration. 

Application name: Cancer: Cancer treatment is another major application segment within the Gamma Knife Market Market Research Report, particularly for tumors located in sensitive brain structures where traditional surgery poses significant risk. Gamma Knife radiosurgery is commonly used for treating benign and malignant brain tumors such as acoustic neuromas, pituitary adenomas, and meningiomas. Clinical studies show that nearly 85% of benign brain tumors treated with Gamma Knife radiosurgery demonstrate effective tumor control. Approximately 60% of oncology centers utilize stereotactic radiosurgery as a complementary treatment to chemotherapy or conventional radiation therapy. Gamma Knife systems allow physicians to deliver radiation doses to tumors with extremely high precision while minimizing exposure to surrounding healthy brain tissue.

Application name: Arteriovenous Malformation (AVM): Arteriovenous malformation treatment is one of the most specialized applications in the Gamma Knife Market Market Outlook due to the complexity of vascular abnormalities in the brain. AVMs occur when abnormal connections develop between arteries and veins, increasing the risk of brain hemorrhage and neurological complications. Approximately 1% of the global population is affected by AVM-related vascular abnormalities, while around 12% of untreated cases may lead to intracranial bleeding. Gamma Knife radiosurgery offers a non-invasive treatment method that gradually closes abnormal blood vessels by delivering precise radiation doses. Clinical outcomes indicate that nearly 70–80% of AVM cases treated with Gamma Knife technology achieve successful vessel obliteration over time. Radiosurgery also reduces the risk of hemorrhage by approximately 50% following treatment. 

Application name: Trigeminal Neuralgia: Trigeminal neuralgia represents a major neurological disorder treated using Gamma Knife radiosurgery within the Gamma Knife Market Market Insights. The condition is characterized by severe facial nerve pain that affects daily activities and quality of life. Medical data indicates that nearly 12 out of every 100,000 individuals experience trigeminal neuralgia, with incidence rates increasing among aging populations. Gamma Knife radiosurgery is considered an effective non-invasive treatment option for patients who do not respond to medication therapy. Clinical studies show that approximately 75–85% of patients undergoing Gamma Knife treatment for trigeminal neuralgia experience significant pain relief within several months following the procedure. 

Application name: Others: Other neurological applications also contribute significantly to the Gamma Knife Market Market Size, including treatment of acoustic neuromas, pituitary tumors, epilepsy, and functional brain disorders. Acoustic neuromas account for nearly 8% of primary brain tumors and are frequently treated using Gamma Knife radiosurgery due to their location near critical cranial nerves. Approximately 90% of acoustic neuroma patients treated with Gamma Knife systems achieve long-term tumor control without invasive surgery. Pituitary adenomas represent another common condition treated with radiosurgery, affecting nearly 16% of individuals diagnosed with brain tumors. 

Gamma Knife Market Market Regional Outlook

Download FREE Sample to learn more about this report.

North America

North America represents the most technologically advanced region in the Gamma Knife Market Market Analysis due to strong healthcare infrastructure and widespread adoption of advanced neurosurgical technologies. The region accounts for nearly 48% of global stereotactic radiosurgery installations, supported by highly specialized neurological treatment centers. More than 120 hospitals and cancer institutes across the region operate Gamma Knife radiosurgery systems to treat complex neurological disorders. Brain metastases affect nearly 200,000 patients annually in the region, creating strong demand for precision radiation therapy solutions. Approximately 68% of neurosurgery departments in major medical institutions incorporate stereotactic radiosurgery into their treatment programs. The presence of advanced oncology care networks also contributes to the expansion of Gamma Knife treatment services. Nearly 55% of patients diagnosed with small intracranial tumors receive radiosurgery rather than conventional open surgery. Increasing neurological disease incidence among aging populations further strengthens demand for minimally invasive treatment technologies. Hospitals across the region are also integrating AI-based treatment planning tools, with around 44% of neurosurgical centers adopting digital radiation dose optimization systems to improve clinical outcomes and patient safety.

Europe

Europe represents a significant region in the Gamma Knife Market Market Trends due to strong public healthcare systems and increasing investment in neurological treatment infrastructure. Approximately 27% of global Gamma Knife radiosurgery installations are located across European neurosurgical centers. More than 80 specialized hospitals in the region operate advanced stereotactic radiosurgery units to treat neurological disorders such as brain tumors, vascular malformations, and trigeminal neuralgia. Neurological diseases affect nearly 179 million individuals across Europe, creating substantial demand for specialized neurosurgical interventions. Approximately 52% of large medical institutions incorporate Gamma Knife radiosurgery as part of their oncology treatment protocols. Additionally, the region reports nearly 65% treatment preference for minimally invasive radiosurgery when managing small intracranial lesions. European hospitals have also increased adoption of advanced imaging-guided treatment planning systems, with nearly 46% of neurosurgical centers implementing MRI-based targeting technologies. Public healthcare funding initiatives continue to expand access to stereotactic radiosurgery services, while research institutions are exploring new neurological applications using Gamma Knife technology to improve treatment outcomes and patient recovery rates.

Asia-Pacific

Asia-Pacific is experiencing rapid expansion in the Gamma Knife Market Market Growth due to increasing healthcare infrastructure investments and rising neurological disease prevalence. Approximately 18% of global Gamma Knife radiosurgery installations are located in this region, with several countries investing heavily in advanced oncology treatment technologies. Neurological disorders affect nearly 12–15% of the population in the region, creating growing demand for precision neurosurgical treatment solutions. More than 70 major hospitals and specialty neurology centers operate Gamma Knife systems to treat brain tumors and vascular abnormalities. Approximately 58% of tertiary care hospitals are expanding stereotactic radiosurgery programs to address the rising burden of cancer-related brain metastases. The region also reports increasing adoption of advanced radiation therapy technologies due to improvements in healthcare infrastructure. Around 49% of newly established neurological treatment facilities incorporate stereotactic radiosurgery capabilities as part of their oncology services. Medical tourism and expanding private healthcare investments are also contributing to the regional expansion of Gamma Knife treatment services, improving accessibility to advanced neurosurgical procedures.

Middle East & Africa

The Middle East & Africa region represents an emerging landscape in the Gamma Knife Market Market Outlook as healthcare modernization programs continue expanding advanced neurosurgical capabilities. Approximately 7% of global stereotactic radiosurgery installations are located in this region, with several large hospitals introducing Gamma Knife treatment centers. Neurological disorders affect nearly 10% of the population across several countries in the region, creating increasing demand for non-invasive treatment technologies. Around 35% of major tertiary hospitals have begun integrating advanced radiation therapy platforms into oncology departments. Investments in cancer treatment infrastructure have also increased significantly, with nearly 42% of healthcare modernization initiatives focusing on oncology and neurological care. Medical institutions are expanding access to precision radiosurgery procedures to improve treatment outcomes for brain tumors and vascular malformations. Approximately 38% of newly developed neurological treatment facilities are incorporating stereotactic radiosurgery equipment. Increasing collaboration with international medical technology providers is also improving access to advanced radiosurgery technologies and supporting growth in specialized neurosurgical treatment programs across the region.

List of Key Gamma Knife Market Market Companies

• Elekta
• Starmap Medicine & Technology
• Accuray
• BrainLab
• GE Healthcare
• Hitachi America
• IBA Group
• Mitsubishi Electric
• Nordion
• Philips Healthcare
• RaySearch
• Sumitomo Heavy Industries
• Varian Medical Systems

Top Companies with Highest Market Share

• Elekta: Elekta accounts for nearly 58% installation presence in dedicated Gamma Knife radiosurgery systems globally, with approximately 65% of neurosurgical centers using its platforms for intracranial treatment procedures. Around 72% of hospitals operating Gamma Knife technology rely on Elekta-developed treatment planning systems due to high precision radiation delivery capabilities.
• Varian Medical Systems: Varian Medical Systems contributes approximately 24% participation in advanced radiosurgery equipment used in stereotactic treatment centers. Nearly 49% of oncology institutions utilizing precision radiation therapy platforms integrate Varian-developed treatment planning software and imaging technologies for radiosurgery optimization and clinical workflow efficiency.

Investment Analysis and Opportunities

Investment activity in the Gamma Knife Market Market is expanding as healthcare systems prioritize precision radiation therapy technologies for neurological treatment. Approximately 54% of healthcare infrastructure investment programs are focusing on oncology and neurosurgical treatment capabilities. Hospitals upgrading neurological treatment facilities are allocating nearly 37% of technology investment budgets toward advanced radiosurgery platforms. Public healthcare modernization initiatives across emerging regions indicate that around 42% of new tertiary hospitals plan to incorporate stereotactic radiosurgery equipment. Private healthcare providers are also increasing investments in advanced cancer treatment technologies, with nearly 46% of specialized oncology centers expanding radiosurgery programs. Investment in digital treatment planning systems has increased by approximately 39% as hospitals adopt AI-assisted radiation optimization technologies. 

New Products Development

New product development in the Gamma Knife Market Market is focused on improving radiation accuracy, treatment efficiency, and patient comfort during stereotactic radiosurgery procedures. Approximately 52% of recent medical technology innovations in radiosurgery systems focus on frameless treatment platforms that eliminate the need for invasive head frames. Advanced imaging integration technologies are also improving treatment planning precision, with nearly 48% of newly introduced radiosurgery systems incorporating MRI-guided radiation targeting features. Additionally, around 44% of new radiosurgery platforms integrate AI-supported treatment planning algorithms that help optimize radiation dose distribution.

Five Recent Developments(2023-2025)

• 2025: Elekta received U.S. FDA 510(k) clearance for Leksell Gamma Knife to treat adults with drug-resistant mesial temporal lobe epilepsy, expanding approved clinical indications.
• 2025: Elekta highlighted the Gamma Knife Esprit platform featuring 192 simultaneous gamma radiation beams and submillimeter treatment accuracy for complex intracranial disorders.
• 2024: South Asia's first Gamma Knife Esprit system was installed at Fortis Memorial Research Institute, extending Elekta's global installed base and clinical adoption.
• 2023: U.S. hospitals continued expanding Gamma Knife utilization for malignant brain tumors, vascular disorders, and functional neurological diseases through advanced stereotactic radiosurgery programs.
• 2023–2025: Manufacturers enhanced Gamma Knife workflows with improved imaging integration, digital treatment planning, and remote collaboration capabilities to increase treatment precision and clinical efficiency.

Report Coverage Of Gamma Knife Market Market

The Gamma Knife Market Market Report provides a comprehensive evaluation of global stereotactic radiosurgery technologies, focusing on technological innovation, clinical applications, and healthcare infrastructure developments supporting precision neurological treatment. The report analyzes key segments including system type, clinical application, and regional adoption patterns to provide detailed Gamma Knife Market Market Insights. Approximately 64% of the analysis focuses on hospital adoption patterns and advanced neurosurgical infrastructure expansion, while nearly 36% evaluates emerging treatment technologies and clinical innovation trends.